A single infusion of Celularity‘s PNK-007 — an investigational cell therapy derived from placental stem cells — is safe and leads to good response rates when administered to multiple myeloma patients a few days after autologous stem cell transplant (ASCT), preliminary results from a Phase 1 trial…
Nektar Therapeutics is launching a first-in-human Phase 1 clinical trial to assess the safety and efficacy of NKTR-255 in adults with relapsed or refractory multiple myeloma and non-Hodgkin’s lymphoma. “We are excited to launch the first-in-human clinical study of NKTR-255, which has…
Health Canada has approved Darzalex (daratumumab), in combination with standard Revlimid (lenalidomide) and dexamethasone, for people newly diagnosed with multiple myeloma who are not eligible for an autologous stem cell transplant. Under priority review, the approval was based on data from the Phase 3…
A combination of Darzalex (daratumumab), Kyprolis (carfilzomib), and dexamethasone increases the time to disease progression or death in  multiple myeloma patients who already have received one to three prior therapies. With those results, the CANDOR Phase 3 trial (NCT03158688), co-sponsored by Amgen and…
GBR 1342, an investigational bispecific antibody developed by Glenmark Pharmaceuticals, was granted orphan drug designation by the U.S Food and Drug Administration (FDA) for the treatment of multiple myeloma patients who have received prior therapies. The FDA’s Office of Orphan Products Development (OOPD) gives this designation to novel…
Evomela, an injectable formulation of melphalan, is now available in China as a high-dose conditioning therapy for people with multiple myeloma who will undergo a stem cell transplant, CASI Pharmaceuticals, its maker, announced. The product is also approved as a palliative treatment for patients who cannot take…
Sleep apnea can drive the development of aggressive multiple myeloma in mice resistant to the cancer, a study found, suggesting that the sleep disorder is a modifiable risk factor for this disease. Treating sleep apnea, breathing that starts and stops repeatedly during sleep (also known as chronic intermittent hypoxia), may…
Treatment with Kyprolis (carfilzomib) once a week is as safe and effective as the twice-weekly regimen used for the initial treatment of multiple myeloma patients, a study of two clinical trials suggests. The study, “Once-Weekly Versus Twice-Weekly Carfilzomib In Patients With Newly Diagnosed Multiple Myeloma: A Pooled Analysis…
Get regular updates to your inbox.